Treatment with lenalidomide, an immunomodulatory anticancer drug, inhibits STAT3Y705 phosphorylation induced with IL-10 in healthy T cells, reversing the T-cell dysfunction induced with CLL [102], indicating the significance of CXCL12/CXCR4 in leukemia treatment. This evidence concerns the gene IL10 and B-cell chronic lymphocytic leukemia.